Xenetic Biosciences, Inc. Under Pressure: Shareholder Activism Threatens Stability and Financial FutureTipRanks Financial Blog • about 1 month ago
Xenetic Biosciences, Inc. (XBIO) has disclosed a new risk, in the Share Price & Shareholder Rights category. Xenetic Biosciences, Inc. faces financ...
Share to Feed
Xenetic Biosciences reports FY results...
Continued advancement of DNase-based oncology program towards Phase 1 clinical study for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumorsEnded the year with...
Xenetic Biosciences Inc (NASDAQ:XBIO Get Free Report) was the target of a significant growth in short interest during the month of January. As of January 15th, there was short interest...
- Company building growing body of preclinical data to guide pathway to first in human trial for DNase-based oncology platformFRAMINGHAM, MA / ACCESSWIRE / January 17, 2024 / Xenetic Biosciences...